trending Market Intelligence /marketintelligence/en/news-insights/trending/yqdojkdaxau2rttgvbn-va2 content esgSubNav
In This List

Aileron Therapeutics' chief medical, scientific officer becomes CEO

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022

Blog

Insight Weekly: CEO pay jumps; yield curve inversion deepens; wind giants lift turbine prices


Aileron Therapeutics' chief medical, scientific officer becomes CEO

Aileron Therapeutics Inc. appointed Manuel Aivado as president and CEO.

Aivado succeeds John Longenecker, who replaced Joseph Yanchik III on an interim basis after he resigned.

Aivado has been the senior vice president and chief medical and scientific officer of the biopharmaceutical company since 2012. He most recently designed and implemented the first-in-human trial of the company's experimental anti-tumor therapy ALRN-6924.